搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
FierceBiotech
3 小时
Intuitive plots full da Vinci 5 rollout for 2025, weighs potential tariff impacts
With the full-scale launch of its latest surgical robot set for the middle of this year, Intuitive said that, to date, the ...
FierceBiotech
5 小时
‘A really rational IPO environment’: What does it takes for a biotech to go public now?
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...
FierceBiotech
7 小时
Chutes & Ladders—Flagship vet plants CEO roots at Pharming
Rare disease drug maker Pharming Group is calling off the search for a CEO successor to longtime chief Sijmen de Vries after ...
FierceBiotech
8 小时
Novo links next-gen obesity drug to 22% weight loss at Week 36
Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...
FierceBiotech
10 小时
Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut
The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...
FierceBiotech
1 天
Flagship Pioneering forges Cambridge connection with UK research institutions
Flagship Pioneering is leveraging its year-old London outpost to forge new research collaborations across the pond. | ...
FierceBiotech
1 天
GSK, Merck and Pfizer in Ab&B's sights as Chinese vaccine biotech files for IPO
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
FierceBiotech
1 天
FDA delays decision on Stealth's 2nd shot at approval for ultrarare disease med
An FDA advisory committee may have ruled in elamipretide’s favor back in October, but it looks like Stealth BioTherapeutics ...
FierceBiotech
1 天
Exicure, back from brink and under new management, buys GPCR's US unit and clinical-stage drug
Exicure was an expiring company with no money or active pipeline. | A couple of months ago, Exicure was an expiring company ...
FierceBiotech
2 天
RFK Jr. pledges to divest interests in CRISPR Tx, Dragonfly if HHS role confirmed
Robert F. Kennedy Jr. will be pulling his investments from two biotechs if he is confirmed to lead the U.S. Department of ...
FierceBiotech
1 天
Biogen research team hit by layoffs as company shifts resources to external opportunities
Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...
FierceBiotech
1 天
Masimo lands new CEO from BD's patient monitoring division
After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈